Cardiac stem cells and methods of identifying and using the same
AssigneeVestion, Inc.
InventorsJoshua HARE, Konstantinos CHATZISTERGOS
Life of this patent
Estimating the term…
Abstract
Methods of isolating cardiac cells, including cardiac cells capable of regenerating cardiac tissue are provided. Compositions comprising cardiac cells, including cardiac cells capable of regenerating cardiac tissue are also provided. Methods of using cardiac cells, cardiac progenitor cells, including cardiac cells capable of regenerating cardiac tissue, are provided. Methods of identifying the prognosis of patients treated for heart disease and/or methods of predicting the regeneration of cardiac cells in a subject are also provided.
Claims28
A method of isolating cardiac progenitor cells from a population of cardiac cells, the method comprising:
- identifying the cardiac progenitor cells in the population as cells comprising phosphorylated retinoblastoma protein;
- and
- isolating the identified cardiac progenitor cells.
3-4. (canceled)
(canceled)
(canceled)
11-13. (canceled)
A method of treating a heart disease in a subject in need thereof comprising administering a therapeutically effective amount of isolated cardiac progenitor cells, wherein the cardiac progenitor cells are isolated according to a method comprising:
- identifying the cardiac progenitor cells in a population as cells comprising phosphorylated retinoblastoma protein;
- and
- isolating the identified cardiac progenitor cells.
A method of isolating cardiac progenitor cells from a population of cardiac cells, the method comprising:
- identifying the cardiac progenitor cells in the population as cells that are positive for phospho-Rbpos or Gata4, and/or negative for ARF, or any combination thereof;
- and
- isolating the identified cardiac progenitor cells.
20-23. (canceled)
(canceled)
A method of isolating regenerative cardiomyocytes from a population of cardiomyocytes, the method comprising:
- identifying the regenerative cardiomyocytes in the population as cells that are positive for at least one marker selected from phospho-Rbpos, Gata4pos, ARFneg, N-cadherinpos, connexin-43pos, Isl1pos, Wt1pos, CDK2pos, CDK4pos, CDK6pos, E2Fpos, phospho-p107pos, phospho-p130pos, CCNApos, CCND1pos, CCND2pos, CCND3pos, CCNEpos, CDKN1aneg, CDKN1bneg, CDKN1cneg, CDKN2aneg, CDKN2bneg, CDKN2cneg, CDKN3neg, c-kitpos, CD3neg, CD14neg, CD68neg, Nkx2.5pos, MITFpos, MEF2cpos, and any combination thereof;
- and
- isolating the identified regenerative cardiomyocytes.
29-48. (canceled)
A method of regenerating cardiac cells in vitro or in vivo, the method comprising contacting the cardiac cells with at least one agent that inhibits the function of retinoblastoma (Rb) or a function of alternate reading frame of Ink4a (ARF) protein.
53-61. (canceled)
Dependencies are inferred from the claim text.